Primary cardiac involvement is a common and severe complication of systemic sclerosis, which may affect all of the hearts' structural components, including pericardium, myocardium, endocardium, cardiac valves, and conduction system. While cardiac disease can be clinically silent and only diagnosed in autopsy, new imaging modalities such as speckle-tracking echocardiography and cardiovascular magnetic resonance may reveal various abnormal findings in the majority of patients. Cardiovascular magnetic resonance evaluation should include assessment of left and right ventricular function, inflammation (STIR T2-weighted sequences (T2-W) for edema detection), and fibrosis (T1-weighted sequences 15 min after Gd-DTPA contrast medium injection (late-gadolinium enhancement). Notably, cardiac disease is responsible for about one-fourth of systemic sclerosis-related deaths. Systematic studies for the assessment and therapy of systemic sclerosis-related cardiac complications, as well as relevant guidelines from the European League Against Rheumatism and the American College of Rheumatology, are currently lacking. However, research advances reviewed herein allow for a better understanding of the mechanisms that alter cardiac function. Implementation of such knowledge should reduce cardiac morbidity and mortality in systemic sclerosis patients.
Introduction
Systemic sclerosis (SSc) is a rare autoimmune rheumatic disease characterized by deregulation of the immune system, vasculopathy, and fibrosis of the skin and internal organs. The prevalence of the disease globally is around 1 in 10,000 people. Both genetic and environmental factors have been implicated in the pathogenesis of SSc; however, the exact mechanisms that underlie its development have not yet been deciphered. A dysfunctional repair of connective tissue in response to injury is currently thought to have a pivotal role in the initiation and propagation of the disease (1) .
Primary cardiac involvement is common in SSc, affecting all of the hearts' structural components, including pericardium, myocardium, endocardium, cardiac valves, and conduction system. Anti-topoisomerase-positive SSc patients are more frequently and more severely affected (2) . While cardiac disease can be silent in patients with SSc and sometimes only diagnosed in autopsy (3) , clinically overt heart involvement is a serious negative prognostic marker, associated with an increased mortality rate (4) .
No guidelines have yet been established by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) for the assessment and therapy
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Prevalence of cardiac involvement and associated mortality
The prevalence of clinical cardiac involvement in SSc varies depending on the sensitivity of the methods used for its detection. For example, with the use of cardiovascular magnetic resonance imaging (CMR), up to two-thirds of patients in some series may have cardiac involvement associated with SSc (7) . Indirect evidence suggests that subclinical cardiac involvement may eventually occur in the vast majority of patients with SSc. An older meta-analysis of cohort studies including 11,526 person-years estimated that clinical heart disease was present in only 10% of SSc patients at any time (8) . After adjusting for age and gender, the authors found that the risk of dying was greater for patients with cardiac involvement (hazard ratio (HR): 2.8; 95% confidence interval (CI): 2.1-3.8) compared to those with renal (HR: 1.9; 95% CI: 1.4-2.5) or pulmonary involvement (HR: 1.6; 95% CI: 1.3-2.2). In contrast, in a recent study from Spain, clinical cardiac involvement was present in up to 44% of SSc patients, accounted for 20% of deaths and was an independent mortality risk factor (HR: 2.1, p = 0.02) (4) . In a large cohort of 821 SSc patients from Italy, recruited between 2000 and 2011, heart involvement, defined as the presence of pericarditis, congestive heart failure, severe arrhythmias, or atrioventricular conduction abnormalities, was reported in 20.5% of patients at the end of follow-up and accounted for 29.1% of deaths recorded. By comparison, in an older cohort of 1012 Italian SSc patients, recruited between 1955 and 1999 by the same group of researchers, heart involvement had a significantly higher prevalence of 35% at the end of follow-up and was responsible for 36% of deaths, which, although higher, was not statistically different from the rate found in the more recent cohort (9) .
However, data from the Spanish Scleroderma registry suggest that heart involvement as a cause of death in patients with SSc has tripled its relative frequency in the years 2000-2009, as compared to the 1990-1999 decade (30.6% vs 12.8%) (10) . A recent analysis of data from the EULAR Scleroderma Trials and Research (EUSTAR) project, including 11,193 patients, indicated that 27% of 1072 deaths, reported over a median follow-up of 2.3 years, were due to cardiac causes. The same study found that in 31% of the 2719 death certificates issued in France between 2000 and 2011 related to SSc, the direct cause of death was cardiac disease (11) . In another recent study seeking to determine mortality and causes of death in a multinational inception cohort of 1070 SSc patients, myocardial involvement accounted for 14.9% of SSc-related deaths and cardiovascular disease accounted for 11.8% of non-SSc-related deaths (12) . Evidently lower figures were found in a prevalent cohort of 3218 SSc patients, where only 9% of SSc-related deaths and 4.7% of non SSc-related deaths resulted from cardiac causes, possibly because prevalent cohorts fail to capture early deaths and could underestimate cardiac mortality in SSc (12) . In other smaller studies, heart disease accounted for 11%-33% of deaths of patients with SSc (13) (14) (15) .
Conduction system defects and arrhythmias: assessment and management
Palpitations represent one of the most commonly encountered complaints among SSc patients. In the EUSTAR database, 6% of SSc-related deaths and less than 1% of nonSSc-related deaths were attributed to arrhythmias (16) . Abnormal electrocardiogram (ECG) findings have been reported in 25%-75% of patients with SSc, they occur early in the disease course and have been associated with older age, pulmonary arterial hypertension (PAH), and more severe heart and lung involvement (17) (18) (19) . In the GENISOS cohort, the most common ECG abnormalities among 265 SSc patients were non-specific ST-T wave changes (12.1%), followed by findings indicative of PAH (11.3%). In the same cohort, complete right bundle branch block was a strong predictor of mortality, independent of age at enrollment, gender, ethnicity, and risk factors for coronary artery disease (17) . In another recent study, a wider spatial QRS-T angle on standard echocardiography was recognized as a strong indicator of ventricular repolarization heterogeneity and could be effectively used as a screening test to identify SSc patients at high risk of life-threatening ventricular arrhythmias (20) .
As far as 24-h Holter recordings are concerned, a study from Sweden showed more frequent abnormalities among SSc patients in comparison to controls (38% vs 17%, p = 0.05) (21) . The mean and the lowest heart rates were significantly higher in patients compared to controls, while the most frequent aberrations reported in patients were supraventricular and ventricular extrasystoles and supraventricular tachycardia (21) . It has been further shown that SSc patients are at a higher risk to develop incident atrial fibrillation in comparison to controls, especially in the presence of left ventricular diastolic dysfunction with left atrium overload. Elevated Btype natriuretic peptide was the only independent predictor of incident atrial fibrillation in this patient population (22) . In a prospective cohort study assessing the role of 24 h Holter monitoring in the management of SSc patients, 56% of patients enrolled had 24 h Holter abnormalities and 24% had frequent ventricular ectopic beats. The later correlated with increased levels of high-sensitive cardiac troponin T and a lower left ventricular ejection fraction on echocardiography (23) . Ventricular ectopic beats above 1190/24 h could identify SSc patients at high risk of life-threatening arrhythmias and sudden cardiac death with 100% sensitivity and 83% specificity (23) . Also, it has been shown that the assessment of heart rate variability and heart rate turbulence on 24 h ECG Holter monitoring can serve as a measure of cardiac autonomic nervous system dysfunction in patients with SSc, while heart rate turbulence can also be useful for the identification of SSc patients at risk of ventricular arrhythmia (18, 24) .
Conduction disease and arrhythmias in patients with SSc should be correlated to ischemic, fibrotic or inflammatory lesions detected by cardiac imaging. In a study including 41 SSc patients, cardiac arrhythmias and conduction disturbances on 24 h Holter recordings were found to correlate with myocardial fibrosis on CMR (25) . In addition, patients with abnormal ECG were more likely to have PAH, low left ventricular ejection fraction (LVEF), increased right ventricular diameter, and late-gadolinium enhancement (LGE) in a greater number of segments in CMR (25) . Furthermore, a recent study evaluating myocardial dysfunction in SSc patients with normal ejection fraction, using speckle-tracking echocardiography (STE), found that patients with abnormal Holter had impaired global longitudinal and circumferential strains and that strain measurements were independently associated with abnormal Holter findings (26) . Finally, ventricular conduction abnormalities have been correlated with septal or anteroseptal thallium perfusion defects but with normal coronary angiography, denoting more advanced myocardial involvement in patients with SSc (27) .
Anti-arrhythmic drug therapy is the mainstay of treatment for cardiac arrhythmias in SSc, and since randomized controlled trials are lacking, therapy should be adjusted to the needs of the individual patient (28) . In this population, specific side effects of anti-arrhythmic medications, such as the potential lung fibrotic effect of amiodarone, should be carefully considered (6) . Class I anti-arrhythmic agents, although not specifically studied, are probably to be contraindicated because of recurrent episodes of ischemia-reperfusion. In case beta-blockers are mandatory in SSc patients, carvedilol and nebivolol, which cause vasodilation through alpha-blockade and through the nitric oxide pathway, respectively, are to be preferred. Drug intolerant or drug-resistant arrhythmias can sometimes be effectively managed with cardiac ablation. High-grade heart conduction blocks may need permanent pacemaker implantation (29) . The indications for pacemaker implantation should be determined using the criteria applicable to the general population (30) . Finally, evidence suggests that in SSc patients affected by ventricular arrhythmias, at high risk of sudden cardiac death, implantation of a cardioverter-defibrillator, whenever indicated as per standard practice, can prove a lifesaving intervention (31) . It is therefore important for the treating physician to maintain a high level of suspicion and frequently screen these patients for potentially lethal arrhythmias.
Pericardial involvement: assessment and management
Pericardial disease, including both acute pericarditis and chronic pericardial effusion, is fairly common in SSc, but not always gives symptoms and only seldom advances to constrictive pericarditis and cardiac tamponade. Patients with the diffuse skin disease subtype have a higher tendency to develop pericarditis compared to those with limited disease form (4). In the EUSTAR database, clinically evident pericardial effusion was found in 8.4% of patients with early SSc (n = 695) and 6.0% of patients in the remaining cohort (n = 9196) (32), while in other smaller studies the prevalence ranged between 13% and 26% (4, 12, 13) . Since pericardial involvement in SSc is mostly asymptomatic, necrotomic findings from 44 patients with SSc and 19 age-and gender-matched controls indicated a much higher prevalence of 77.5% for chronic pericarditis in the SSc group compared to 5.2% in the control group (33). Likewise, earlier autopsy studies reported pericardial involvement in the range of 33%-72% in SSc cases.
Histologically, the affected pericardium in SSc was characterized by chronic inflammatory infiltrates and a significant increase in fibrous tissue (33) . In a small study from Thailand, the pericardial fluid analysis of all nine SSc patients who underwent pericardiocentesis revealed exudative characteristics (34) . The presence of pericardial effusion should not be ignored as it could be a clue of impending scleroderma renal crisis or indicate the presence of PAH associated with poor prognosis (35, 36) . Importantly, the co-existence of PAH and pericardial effusion may each hinder or delay the diagnosis of the other, since pulmonary artery pressure can be reduced in case of cardiac tamponade and right ventricular collapsus can be absent or less pronounced in patients with severe PAH. Cardiac tamponade is a very rare, but severe complication of SSc, with a mortality rate of 55% (36) . To date, 33 cases of SSc patients that developed cardiac tamponade have been reported (36) (37) (38) (39) .
Among various imaging modalities proposed for the evaluation of pericardial disease, echocardiography is the main technique for diagnosis, follow-up, and management of pericardial effusion. Echocardiography can give information both on size and location of the fluid, as well as on related hemodynamic changes, and provide guidance in pericardiocentesis (40) . Cardiac computed tomography (CT) scan and CMR are reserved for cases of localized effusion and can also be useful for the investigation of other systems and organs, such as the lungs. In addition, CMR can provide information on pericardial tissue and fluid characteristics and may help in the differentiation of constrictive pericarditis (40) . Moreover, despite the fact that fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan is not indicated for investigation of pericardial disease, it could be used to measure metabolic activity within the pericardium (41) .
Acute pericarditis related to SSc usually responds well to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine, alone or with aspirin (30) . Corticosteroids should be used with caution, only in cases refractory to the above treatment, as they are known to precipitate sclerodermal renal crisis and also increase the risk of chronic symptomatic pericarditis (30, 39) . Azathioprine, cyclophosphamide, and mycophenolate sodium have been used in patients who do not respond to corticosteroids (42) . Poor outcomes have been reported with pericardiocentesis in patients with SSc and large pericardial effusions or tamponade, especially when associated with PAH. The exact mechanism for this is not understood; however, it has been suggested that fluid removal from the pericardium allows a volume overloaded right ventricle (RV) to enlarge and hinder left heart filling, ultimately resulting in hypotension and death (36) .
Primary myocardial disease
The histopathologic hallmark of primary myocardial disease in SSc is the presence of contraction band necrosis with replacement fibrosis (43) . Fibrotic areas range from 8% to 32% of heart biopsy samples obtained from SSc patients, as opposed to <3% in heart biopsies obtained from controls (44) . Various degrees of inflammation, consisting mostly of CD3 T-lymphocytes and activated major histocompatibility complex class II (MHC II)-positive CD68 macrophages, almost always coexist and are invariably localized within areas of fibrosis. Interestingly, remodeling of intramyocardial vessel walls has also been described in SSc patients, with prominent hyperplasia of smooth muscle cells and fibrosis, leading to severe concentric narrowing of the vessel lumen (44) . By contrast, the extramural coronary arteries in the majority of SSc patients have been found to be patent (43) , although some studies have recognized an increased frequency of coronary artery disease among SSc patients (45) . Furthermore, CMR studies have shown that in SSc, fibrosis frequently spares the subendocardium, while this is not the case in atherosclerotic coronary artery disease (7) .
In terms of pathophysiology, myocardial impairment in SSc is thought to result from a defective microcirculation, leading to repeated ischemia-reperfusion injury and culminating in the development of fibrosis (46) . The histological findings of patchy fibrosis and focal myocardial necrosis of the contraction band type that are not associated with coronary artery disease are strongly suggestive of a reperfusion lesion, whereas a functional "Raynaud phenomenon" of the heart may also be involved (43) . In fact, severe cardiac Raynaud phenomenon is a long-term predictor of left ventricular systolic dysfunction in SSc patients (47) . Reversible myocardial perfusion defects during cold challenge in SSc patients have been shown by measurement of thallium uptake using imaged single-photon emission computed tomography (SPECT) or PET, further enhancing the notion of a myocardial Raynaud phenomenon (48) . In addition, impairment in coronary microvasculature, as indicated by reduction in coronary flow reserve, has been shown in SSc patients, not only by heart catheterization (49) but also by contrast-enhanced transthoracic Doppler during adenosine infusion (50) . Furthermore, contrast-enhanced CMR can also detect perfusion defects in SSc, accurately and early in the disease course. In a recent study, myocardial hypoperfusion was found in 53.8% of SSc patients compared to none of the controls and co-localized with delayed contrast enhancement, indicative of fibrosis (51) . Finally, stress CMR has been used to investigate myocardial perfusion in asymptomatic dcSSc patients, showing a significant reduction in myocardial perfusion reserve index (MPRI) compared with matched healthy controls (52) .
Primary myocardial disease in SSc can manifest as asymptomatic left ventricular systolic and/or diastolic dysfunction or as overt heart failure of the left or RV (53), as described below. Recent advances in treatment of SSc-related myocardial involvement are also presented below.
Assessment of left ventricular involvement
Left ventricular systolic dysfunction is considered the hallmark of primary myocardial involvement in SSc and can be detected by either routine echocardiography or at an earlier stage by more refined echocardiography techniques such as tissue-Doppler imaging and speckle-tracking strain analysis (54) . However, left ventricular diastolic dysfunction, as an early consequence of myocardial fibrosis, is more common in SSc compared to controls, but its prevalence varies according to the methods used for its evaluation (55, 56) . In order to eliminate this source of confusion, the adoption of the recommendations for the evaluation of left ventricular diastolic dysfunction recently issued by the American Society of Echocardiography and the European Association of Cardiovascular Imaging is considered mandatory in all future studies (57) . Although it is still a matter of debate if diastolic dysfunction in SSc is most often primary or secondary to other cardiac abnormalities (58) , its presence is associated with worse survival (55) . In a recent cross-sectional study of 300 SSc outpatients, left ventricular diastolic dysfunction was recognized in 44% and was related to advanced age, systemic hypertension, and lung complications of SSc. Significantly more deaths were reported in the left ventricular diastolic dysfunction group (p < 0.0001) (59) .
Tissue Doppler imaging (TDI), a relatively new echocardiography technique allowing the measurement of myocardial tissue velocity, permits the identification of diastolic dysfunction better than conventional echocardiography and should be considered for routine patient evaluation (60) . Moreover, TDI could measure myocardial strain and strain rate, indices of cardiac deformation that have been proposed as markers of subclinical systolic and diastolic dysfunction (61, 62) . In the current era of multimodality imaging, STE, a novel technique, is the method of choice to determine the myocardial strain that occurs in longitudinal, circumferential, and radial directions (62) . In the last few years, several studies have used STE to reveal subtle subclinical abnormalities in systolic or diastolic and atrial function of SSc patients (63) (64) (65) . More specifically, STE can be used to detect left ventricular systolic impairment occurring primarily in the basal segments, even in SSc patients with preserved LVEF (Fig. 1) (63) . In addition, two recent studies using STE to evaluate left atrial volume and function in SSc patients without clinically evident cardiac involvement and in controls showed that this method is sensitive enough to assess impairment of left atrial mechanics (64) even in the absence of changes in left atrial size and volume (65) . STE has also proven invaluable for detecting deterioration of these parameters during patient follow-up (66) . Also, a new speckle-tracking tool, not yet investigated in SSc, can determine myocardial strain in all three layers of myocardial wall. Possibly, in the near future, this technique will be able to distinguish subtle abnormalities according to the location of myocardial fibrosis (67, 68) .
A reliable technique to non-invasively detect myocardial fibrosis, inflammation, and perfusion defects of the left heart is CMR (69) . Late-gadolinium-enhanced images allow the recognition of focal myocardial fibrosis in the form of bright areas on a black background (Fig. 2) , and T1 mapping can provide a similar quantitative assessment of diffuse myocardial fibrosis, while T2-weighted imaging and more specifically T2 mapping can recognize and quantify the severity of myocardial edema in SSc patients (70) . Myocardial fibrosis, as detected with LGE in CMR, was found in 15%-66% of SSc patients in different series (25, 71, 72) . In the majority of patients, fibrosis was mid-wall, showing a linear pattern, unrelated to coronary distribution and mostly sparing sub-endocardial layers. Substantially fewer patients had a patchy nodular pattern (71) . In fact, in one study, the linear pattern correlated with dcSSc, while the patchy nodular pattern of fibrosis correlated with lcSSc (71). However, LGE represents only replacement fibrosis and not diffuse interstitial fibrosis, which is commonly found in SSc. The application of T1 mapping techniques and extracellular volume (ECV) fraction offered the potential of a more detailed assessment of myocardial fibrosis even in those with negative LG (73, 74) . ECV fraction quantification in CMR can identify subclinical left ventricular abnormalities in SSc patients reflecting an increase in diffuse myocardial fibrosis, even early in the course of the disease when LGE imaging of the heart is normal (73) . Noteworthily, in one study, these early CMR indices of interstitial myocardial remodeling were also associated with interstitial remodeling of the skeletal muscles in SSc patients (74) . Furthermore, CMR is capable to measure myocardial strain using tagging technique (75) . Interestingly, abnormalities of radial and circumferential myocardial strain in CMR have been associated with myocardial LGE, a marker of fibrosis (76) . In a small retrospective study of 20 SSc patients with biopsy-proven cardiac involvement, CMR, which was obtained prior to biopsy, was assessed for the following five factors: pericardial effusion; pathologic left or right ventricular contractility; reduced left and/or right ventricular ejection fraction; fibrosis and/or inflammation as indicated by LGE; and right ventricular dilatation. Notably, the presence of at least three of the above findings in CMR could predict the biopsy result, whereas the initial clinical evaluation blinded to the subsequent histopathologic work-up provided true positive diagnoses in only 30% of the cases (77) .
To date, there is no official ACR/EULAR recommendation on the appropriate implementation of the different diagnostic modalities available for the assessment of cardiac involvement in SSc. Due to their wide availability, low cost and lack of ionizing radiation, classic echocardiography, and its novel refinements (TDI and/or STE) should be used first for the detection and yearly follow-up of subclinical or overt cardiac dysfunction in all patients, even those who are asymptomatic. A standardized Scleroderma Doppler Echocardiography protocol has been proposed by the UK Systemic Sclerosis Study Group (6) . According to the clinical scenario and the findings of the initial assessment, further testing with contrast and stress echocardiography, CMR, SPECT, right heart catheterization, or coronary angiography could also be needed (Fig. 3) . It should be noted that both echocardiography and CMR are radiation free, which is a significant advantage over CT and nuclear imaging, as radioprotection is an issue in these patients, who are usually females, often quite young at first diagnosis, and usually undergo a not-negligible amount of radiographic examinations (mainly chest CTs) during the course of their disease. Despite some limitations concerning mostly its low availability, lack of portability, and high cost, CMR is currently one of the strongest players in the diagnostic arena of SSc cardiovascular imaging, owing to its capability to perform tissue characterization and reliably discriminate myocardial inflammation from fibrosis, even in asymptomatic patients (Fig. 4) . Moreover, it is less operator-dependent and has a better reproducibility compared to both two-dimensional (2D) and three-dimensional (3D) echocardiography, specifically in patients with poor acoustic window, severe lung disease and dilated ventricles, as is the case in the majority of SSc patients. The UK Systemic Sclerosis Study Group consensus for the management of cardiac disease in SSc proposes that CMR should be performed when indicated by echocardiography findings, such as regional wall motion abnormality, and also in SSc patients with troponin rise, left or RV dysfunction, notable or increased pericardial effusion, and raised N-terminal pro-brain natriuretic peptide (NT-proBNP) levels that cannot be better explained by other conditions, such as PAH, chronic lung disease, or coronary artery disease (6) .
Assessment of right ventricular involvement
The RV, disregarded for years, has now been recognized for its importance and its association with mortality in a variety of heart conditions (78, 79) . In SSc, the RV can be affected either primarily from direct myocardial involvement or secondarily due to PAH, interstitial lung disease, or left heart dysfunction, including systolic/diastolic dysfunction of the left ventricle and valvular abnormalities of the mitral and aortic valve (80) .
In addition, several studies in SSc patients have shown impairment of right ventricular systolic and/or diastolic function, independently from PAH or lung disease. This could imply a direct involvement, similar in pathophysiology to the involvement of the left ventricle (81) (82) (83) (84) . In a recent large study, diastolic dysfunction was more predominant than systolic, and several factors such as primary heart disease, vascular lung disease, and PAH contributed to it (82) . Also, other studies have shown reduced RV ejection fraction and RV dilatation (77) , further enhancing the notion of a primary RV impairment in SSc. Altered RV ejection fraction has been reported as a poor prognostic factor in PAH and other clinical conditions, such as heart failure, reduced LVEF, or ischemic cardiomyopathy (85) . However, some researchers have questioned the possibility of a direct impairment of the RV in SSc and propose that right ventricular dysfunction is rather a result of latent PAH, which could probably be unmasked by exercise echocardiography (86) .
Exercise stress echocardiography, although not accepted to define the presence of exercise pulmonary hypertension, is a very versatile tool to assess not only regional wall motion abnormalities but also non-invasive hemodynamics that may help to better characterize patients' symptoms and to better understand the heterogeneity of the mechanisms underlying exercise-induced increase in pulmonary artery systolic pressure (PASP; latent PAH with high pulmonary vascular resistance, increase in left ventricular filling pressure due to diastolic dysfunction or worsening valvular heart disease) (87, 88) .
The development of 3D echocardiography has permitted the estimation of RV ejection fraction with precision comparable to that of CMR, which currently represents the gold standard modality (78, 89, 90) . Recently, Pigatto et al. (91) reported that RV volume and ejection fraction estimated with 3D echocardiography were reduced in SSc patients, a finding possibly related to volume overload. Also, STE has been used to measure RV strain (83, (92) (93) (94) (Fig. 4) , and interestingly, in a recent study, a unique pattern of alteration in longitudinal strain was found in SSc patients without PAH (95) .
Finally, as mentioned above, CMR is the gold standard imaging method to assess RV size and function without geometric assumption and should be used in each questionable case, as it has the ability to detect signs of both inflammation and fibrosis in the thin RV wall (78, 89, 96) .
The role of biomarkers in the assessment of myocardial involvement
In the last few years, there has been increasing interest in the role of several biochemical markers for the prognostic assessment as well as for the screening of cardiac involvement in SSc. NT-proBNP is a widely used diagnostic screening tool that can readily differentiate between patients with normal and reduced LVEF. Median serum NT-proBNP level was significantly higher in SSc patients, specifically those with cardiac involvement and correlated positively with echocardiographic signs of RV overload and negatively with LVEF (97, 98) . At a cut-off level of 50 pmol/L, NT-proBNP was a strong predictor of heart involvement (odds ratio (OR): 78, 95% CI: 14-424) with a sensitivity of 90.5% and a specificity of 97.6%. However, higher levels of NT-proBNP did not predict survival of SSc patients with heart involvement (98). In addition, increased BNP and NT-proBNP have been associated with the occurrence of PAH in SSc patients and have been incorporated in screening algorithms used to diagnose this condition (99, 100) . Baseline reference measurement and annual monitoring of NT-proBNP in asymptomatic patients, thereafter, has been proposed in the consensus issued by the UK Systemic Sclerosis Study Group (6). Although not extensively studied, other potential cardiac biomarkers in SSc include high-sensitivity cardiac troponins (hs-cTn). Troponin I in particular is considered to be more sensitive as it has exclusively myocardial origin. High-sensitivity cardiac Troponin T has been found significantly increased in SSc patients compared with controls, and along with NT-proBNP, it had a high negative predictive value for precapillary pulmonary hypertension in this population (101) . Finally, in another recent study, higher NT-proBNP and high-sensitivity cardiac Troponin I levels were found in SSc patients compared with controls, both of which were associated with the presence of echocardiographic abnormalities (102) .
Management of myocardial disease
Despite the increasing prevalence and the high morbidity and mortality associated with myocardial involvement in SSc, very few studies have focused on the management of this condition. In any case, the treatment of SSc patients having myocardial involvement should be consistent with heart failure guidelines, either with reduced or with preserved LVEF (103) . Prevention therapy, for example, with calcium channel blockers, may also be considered based on the pathophysiology of the disease and the results of cohort studies (104) . The BSR recommendations for cardiac disease in SSc suggest the use of immunosuppression as well as angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers (carvedilol) for systolic heart failure, while diuretics and calcium channel blockers should be considered in patients with diastolic heart failure and preserved LVEF (5) . Cardiac resynchronization for diastolic dysfunction associated with left bundle branch block and heart transplantation for terminal systolic dysfunction have also been suggested by the UK Systemic Sclerosis Study Group consensus as a possible solution for advanced cardiac involvement in SSc. However, the experts admit that there is a lack of published information regarding cardiac transplantation in the SSc population and the procedure could carry substantial risks (6) . Finally, the implantation of automatic implantable cardioverter-defibrillator (AICD) is needed to prevent sudden cardiac death in SSc patients with a history of ventricular tachycardia in routine ECG or 24 h Holter recording.
Several older studies using Thallium-201 SPECT have shown a promising role for vasodilators, such as nifedipine, nicardipine, and captopril, in improving myocardial perfusion in SSc patients (105) . An improvement in myocardial perfusion of SSc patients has also been shown for nifedipine and bosentan using CMR (106, 107) . Likewise, an increase in myocardial perfusion associated with an enhancement in myocardial energy metabolism was shown in nine SSc patients treated with nifedipine, using PET with a perfusion tracer (potassium-38) and a metabolic tracer (18F-FDG) (108) . Finally, an improvement in LV diastolic and systolic echocardiographic indices was noted in 22 SSc patients following 1-year treatment with captopril (109) . The important role of vasodilators in treating and potentially preventing progression of microvascular heart disease in SSc was further confirmed by the results of a large observational study from France. In this study, which included 7073 SSc patients, older age, male gender, digital ulceration, myositis, and lung involvement were independently associated with LV dysfunction, defined as LVEF <55% by conventional echocardiography, while calcium channel blockers seemed to be protective (OR: 0.41; 95% CI: 0.22-0.74) (104) .
In SSc patients who develop myocarditis, timely initiation of immunosuppressive treatment, such as cyclophosphamide and corticosteroids (110) , is considered to halt or delay progression of cardiac dysfunction. It is possible that a subclinical but impaired myocardial performance can be improved by moderate corticosteroid doses in the short term (111) , but this still needs to be confirmed by double-blind controlled studies. Again it should be stressed that caution is needed when administering high-dose corticosteroids to SSc patients as they can precipitate renal crisis. According to the UK Systemic Sclerosis Study Group consensus, a moderate dose of corticosteroids, under 15 mg/day, in addition to cyclophosphamide pulses could be a reasonable approach for SSc cardiomyopathy (6) . In a recent study from Italy assessing recent-onset cardiac involvement in a cohort of 181 SSc patients, 7 developed histologically confirmed myocarditis (active/acute in 6 cases and borderline/chronic in 1 case). All patients were treated with immunosuppressives for at least 12 months and followed-up for 5 years. Treatment ameliorated symptoms and normalized cardiac enzymes in all 7 patients. Nevertheless, 2 patients died of sudden death during follow-up (112) . Resolution of sclerodermatous myocarditis has also been reported in 1 case following autologous stem cell transplantation (113) .
Valvular heart disease: assessment and management
Clinically significant valvular disease is rare in SSc, as shown by echocardiographic studies and autopsy specimens (30) . According to a large multicentre study from France, including 570 SSc patients, grade II and grade III-IV mitral regurgitation was observed in 6.7% and 0.4% of patients, respectively, while grade II aortic regurgitation was found in 2.5% of patients. None of the participants had grade III-IV aortic regurgitation. Moreover severe aortic stenosis (aortic valve area (AVA) <1 cm 2 ) was noted in only 3.3% of SSc patients (114) . By contrast, a much higher prevalence of valvular heart disease was reported in another study from Spain, not designed to assess the degree of valvular pathology, where mitral and aortic regurgitation were found in 67% and 30%, respectively (4). The most common abnormality described in the literature is nodular thickening of the valves (Fig. 2 ) (30). Doppler echocardiography and more recently 3D echocardiography are the imaging modalities of choice to assess, follow-up, and guide treatment in valvular heart disease in SSc patients (115) .
As is the case in the general population, treatment of valvular heart disease in SSc patients depends on the type and severity of the valve lesion. Asymptomatic patients at a low risk of developing complications are usually closely observed until surgical indications develop. No pharmacological therapy has been shown to improve clinical outcomes in patients with chronic valvular heart disease. However, some medications, such as ACE-inhibitors, long-acting nifedipine, or β-blockers have been tried in acute valvular diseases or as a bridge to surgery in severely decompensated patients, despite the fact that studies show inconsistent results regarding their efficacy (116) . Based on two recently published case reports of SSc patients with aortic valve stenosis, valve replacement in this setting is justified, provided care is taken to avoid hemorrhagic complications and regurgitation during intubation, as well as hypothermia during cardiopulmonary bypass to prevent induction of Raynaud's phenomenon (117, 118) . One additional report described a case series of six SSc patients with severe aortic stenosis who successfully underwent transcatheter aortic valve implantation (TAVI), suggesting that, where indicated, this procedure is a feasible alternative for the management of this high-risk population (119) .
Potential cardiotoxicity of treatment modalities used for SSc
Scarce evidence exists to suggest a possible cardiotoxic effect of the immunosuppressive medication commonly used in SSc. Cyclophosphamide can cause acute cardiotoxicity only after administration at high doses, such as those used in most conditioning regimens for hematopoietic stem cell transplantation (HSCT). In its most severe form, cardiotoxicity related to cyclophosphamide can manifest as hemorrhagic necrotic perimyocarditis, carrying a risk of sudden death. Metabolism of cyclophosphamide to acrolein seems to be implicated in its toxic effect on the heart (120). With the exception of SSc patients undergoing HSCT (121) , no other cases of cyclophosphamide-related cardiotoxicity in SSc have been described in the literature.
Mycophenolate mofetil seems to be a safe choice for the treatment of SSc in terms of cardiotoxicity. Methotrexate has been rarely associated with potentially lethal cardiac rhythm disturbances, an effect independent of drug dosage and possibly related to an idiosyncratic predisposition of patients to arrhythmia (122) . In addition, case reports of methotrexate-induced pericarditis and pericardial effusion have been reported (123) , but none of these side effects have been described in SSc patients. Other medications almost universally used in SSc, such as proton pump inhibitors, have recently been associated with an increased risk of major cardiovascular adverse events (124, 125) .
Among vasodilating drugs commonly administered for SSc-related vasculopathy, bosentan has been reported to cause palpitations, hypotension, and fluid retention and requires caution when given to patients with concomitant left ventricular failure. Likewise, iloprost is contraindicated in patients with severe coronary heart disease, recent cardiovascular or cerebrovascular thromboembolic events, congestive heart failure, or severe arrhythmias as it can aggravate these conditions. Finally, calcium channel blockers are contraindicated in unstable angina and recent myocardial infarction. Reported cardiac adverse events of these medications include tachycardia, palpitations, hypotension, and syncope (6).
Conclusion
Heart involvement remains a major problem in patients with SSc, in which the combination of cardiac Raynaud's phenomenon, inflammation, and fibrosis of the cardiac tissues can ultimately lead to heart failure or potentially lethal cardiac arrhythmias. Recent advances in imaging modalities and an increased awareness among physicians have led to an increased incidence and an earlier diagnosis of heart complications in SSc. Myocardial impairment bears the worst prognosis among all other forms of SSc-related heart disease. The role of the right heart has recently been reappraised, as it has been recognized that right ventricular diastolic and/or systolic dysfunction can exist independently of lung fibrosis or PAH in SSc patients, possibly representing a direct involvement of the RV analogous to that observed in the left ventricle. Despite progress made in the diagnostic approach of heart complications of SSc, their treatment still remains empiric and largely symptomatic. Randomized controlled studies are lacking and therefore the potential therapeutic role of immunosuppressive or vasodilating agents have not been fully assessed. In fact, no formal guidelines exist about heart involvement in SSc, and recommendations regarding both diagnosis and management are urgently needed.
